Clinical Trials Browser

Phase 1 × mirvetuximab soravtansine × 90 days × Clear all

NCT05483933 2025-12-23

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Phase 1 Completed

86 enrolled 17 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms